Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

187.85 +2.53 (+1.37%)
Streaming Delayed Price Updated: 9:55 AM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 639,294
Open 187.77
Bid (Size) 187.73 (4)
Ask (Size) 187.91 (1)
Prev. Close 185.32
Today's Range 187.49 - 189.91
52wk Range 135.85 - 187.71
Shares Outstanding N/A
Dividend Yield 3.15%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss. 
Via Investor's Business Daily
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga

Performance

YTD
+17.54%
+17.54%
1 Month
+10.26%
+10.26%
3 Month
+16.16%
+16.16%
6 Month
+14.26%
+14.26%
1 Year
+26.46%
+26.46%

More News

Read More
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
7 Stocks Set for a Major Bull Run
Via InvestorPlace
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Via MarketBeat
3 High-Yield Dividend Stocks That Are Looking Super Hot
Via InvestorPlace
3 Dividend-Paying ETFs to Secure Your Passive Income Stream
Via InvestorPlace
Topics ETFs
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Via Benzinga
Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why AbbVie Stock Was Cruising Higher on Thursday
Via The Motley Fool
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Economy
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
Via InvestorPlace
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
Via Benzinga
Topics Earnings
Exposures Financial
AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Is AbbVie the Best Dividend Stock for You?
Via The Motley Fool
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
Via InvestorPlace
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.